Showing results (971-980 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|October 8, 2011
Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1Keith D Tardif, Aaron Rogers, Jared Cassiano, et al.
Molecular Cancer Therapeutics|October 8, 2011
Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humansHyun-Seuk Moon, John P Chamberland, Konstantinos Aronis, et al.
Molecular Cancer Therapeutics|October 14, 2011
Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell linesBhaswati Sarcar, Soumen Kahali, Antony H Prabhu, et al.
Molecular Cancer Therapeutics|December 16, 2011
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212Junping Jing, Joel Greshock, Joanna Dawn Holbrook, et al.
Molecular Cancer Therapeutics|December 29, 2011
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumorsRazelle Kurzrock, Nash Gabrail, Chandtip Chandhasin, et al.
Molecular Cancer Therapeutics|December 17, 2011
Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancerPeter M Wilson, Melissa J LaBonte, Heinz-Josef Lenz, et al.
Molecular Cancer Therapeutics|January 12, 2012
TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapiesChristian T Hellwig, Markus Rehm
Molecular Cancer Therapeutics|February 10, 2012
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activityJoyce James, Bruce Ruggeri, Robert C Armstrong, et al.
Molecular Cancer Therapeutics|February 4, 2012
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cellsVikas Sehdev, DunFa Peng, Mohammed Soutto, et al.
Molecular Cancer Therapeutics|February 11, 2012
Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategyW Nathaniel Brennen, John T Isaacs, Samuel R Denmeade
Pageof 599